Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting
Following the first- and second-line of treatment, inetetamab- containing combinations demonstrated promising clinical activity and a manageable safety profile in patients with HER2-positive MBC, especially in the first-line treatment.
Authors
- Liang Xu (ORCID: https://orcid.org/0000-0001-8946-8280)
- Qingmo Yang (ORCID: https://orcid.org/0000-0002-6904-9772)
- Yuxin Mu (ORCID: https://orcid.org/0000-0002-8465-6933)
- Wanping Liang
- Xiaowei Qi (ORCID: https://orcid.org/0000-0002-5876-4957)
- Xuefeng Xu (ORCID: https://orcid.org/0000-0001-7148-846X)
- Jianguo Zhang (ORCID: https://orcid.org/0000-0001-7057-2862)
- Hui Zhang (ORCID: https://orcid.org/0000-0001-8803-2696)
- Chao Deng (ORCID: https://orcid.org/0000-0002-1994-949X)
- Lu Gan (ORCID: https://orcid.org/0000-0003-4116-8830)
- Jiao Yang
Institutions
- Fujian Medical University (CN)
- Shanghai Medical College of Fudan University (CN)
- Army Medical University (CN)
- Hebei North University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Zhangjiakou Academy of Agricultural Sciences (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Chongqing Three Gorges Central Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Southwest Hospital (CN)
- Fujian Provincial Hospital (CN)
- Anyang Tumor Hospital (CN)
- Chongqing Three Gorges University (CN)
- Chongqing Medical University (CN)
- Northern College (CA)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.3389/fonc.2025.1564888
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Chinese Society of Clinical Oncology